Guest Editor: Francesco Di Bello, MD University of Naples Federico II: Naples, Campania, IT. Email: fran.dibello12@gmail.com Website: https://orcid.org/0000-0002-8585-3701

Guest Editor: Dr. Andrea Gallioli Fundacio Puigvert, Barcelona, Spain Email: andrea.gallioli@gmail.com Website: https://www.sciencedirect.com/author/57221822809/andrea-gallioli

Renal cell carcinoma (RCC) remains a paradigmatic example of how molecular discoveries can reshape clinical practice. Over the past decade, advances in cancer genomics and immunobiology have uncovered key mechanisms driving RCC development and progression—from VHL/HIF dysregulation and metabolic reprogramming to immune escape pathways. These insights paved the way for the precision medicine development, guiding the design of targeted and immune-based therapies that are rapidly transforming patient outcomes.
At the same time, in surgical management of RCC, a new era of minimal invasiveness has started. Robotic and laparoscopic techniques have refined the standards of nephron-sparing surgery, while image-guided focal therapies such as cryoablation and radiofrequency ablation are expanding the armamentarium for localized disease and comorbid patients. This convergence of molecular understanding and technological innovation is redefining how we diagnose, stratify, and treat RCC across its spectrum.
This Special Issue, “Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches”, invites contributions that explore the molecular foundations of RCC and their translation into clinical practice. We particularly welcome original studies and reviews addressing biomarkers, molecular targets, immune modulation, and advances in minimally invasive and image-guided therapies. Together, these insights aim to bridge the gap between bench and bedside, moving toward truly personalized management of RCC.

Keywords: Renal cell carcinoma; molecular mechanisms; precision oncology; targeted therapy; immunotherapy; biomarkers; robotic surgery; focal therapy; minimally invasive treatment; translational research.
 

Manuscript Submission Information

Manuscripts should be submitted online at www.antpublisher.com through the online submission system. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, Review articles as well as Therapeutic Brief are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. UTJ is an international peer-reviewed open access quarterly journal published by ANT.

Please visit the Instructions for Authors page before submitting a manuscript. Considering limited grants for some researchers,  Prof. Shahrokh F. Shariat and the editorial office made the decision that Article Processing Charges will be fully exempted, which means that there is  NOT any manuscript processing or publication fees  for your article once accepted after standard peer-review.

Submission Deadline

May 31, 2026

Participants

Contacts

Updated on November 04, 2022